Müller-Decker K, Kopp-Schneider A, Marks F, Seibert K, Fürstenberger G
Research Program Tumor Cell Regulation, Deutsches Krebsforschungszentrum, Heidelberg, Germany.
Mol Carcinog. 1998 Sep;23(1):36-44. doi: 10.1002/(sici)1098-2744(199809)23:1<36::aid-mc5>3.0.co;2-f.
The growth factor- and phorbol ester-inducible prostaglandin H synthase (PGHS)-2 has been found to be constitutively overexpressed in epidermal tumors generated by the initiation-promotion protocol in murine skin, whereas the expression of PGHS-1 does not change under these conditions. In this paper we report the intra-tumor distribution of the aberrantly expressed PGHS-2 and the cancer chemopreventive activity of a specific PGHS-2 inhibitor. By immunohistochemical methods using isoenzyme-specific antibodies, we found that the PGHS-1 protein was expressed in keratinocytes and Langerhans cells dispersed throughout the epithelial part of papillomas and squamous cell carcinomas and in inflammatory infiltrates occasionally seen in these tumors. A uniform pattern of PGHS-2 expression was observed in the basal keratinocytes of papillomas and in the follicular keratinocytes of carcinomas. In addition, Langerhans cells as well as tumor-associated inflammatory infiltrates exhibited PGHS-2-specific immunoreactivity. PGHS-2-catalyzed prostaglandin synthesis stimulated by the phorbol ester 12-O-tetradecanoylphorbol-13 acetate (TPA) in mouse epidermis in vivo was dose-dependently suppressed by topical administration of SC-58125, a specific PGHS-2 inhibitor. TPA-induced edema formation, epidermal DNA synthesis, and mitotic activity were not impaired by SC-58125 applied at a dose that inhibited TPA-induced prostaglandin E2 synthesis. However, the repetitive epicutaneous administration of SC-58125 substantially and significantly suppressed papilloma development. Malignant progression of papillomas was slightly retarded by the drug. These results indicate that aberrant expression of PGHS-2 in epidermal tumors may be a relevant target for prevention of epidermal cancer development in experimental animals and that the PGHS-2-specific inhibitor SC-58125, which is a potent inhibitor of tumor promotion in mouse skin, may be important for cancer chemoprevention in humans as well.
生长因子和佛波酯诱导型前列腺素H合酶(PGHS)-2已被发现,在通过启动-促进方案诱导产生的小鼠皮肤表皮肿瘤中持续过度表达,而在这些条件下PGHS-1的表达没有变化。在本文中,我们报告了异常表达的PGHS-2在肿瘤内的分布以及一种特异性PGHS-2抑制剂的癌症化学预防活性。通过使用同工酶特异性抗体的免疫组织化学方法,我们发现PGHS-1蛋白在分散于乳头状瘤和鳞状细胞癌上皮部分的角质形成细胞和朗格汉斯细胞中表达,并且在这些肿瘤中偶尔可见的炎性浸润中也有表达。在乳头状瘤的基底角质形成细胞和癌的毛囊角质形成细胞中观察到PGHS-2的均匀表达模式。此外,朗格汉斯细胞以及肿瘤相关的炎性浸润均表现出PGHS-2特异性免疫反应性。在体内,小鼠表皮中由佛波酯12-O-十四烷酰佛波醇-13-乙酸酯(TPA)刺激的PGHS-2催化的前列腺素合成,通过局部施用特异性PGHS-2抑制剂SC-58125而呈剂量依赖性抑制。以抑制TPA诱导的前列腺素E2合成的剂量施用SC-58125,不会损害TPA诱导的水肿形成、表皮DNA合成和有丝分裂活性。然而,重复经皮施用SC-58125可显著抑制乳头状瘤的发展。该药物略微延缓了乳头状瘤的恶性进展。这些结果表明,表皮肿瘤中PGHS-2的异常表达可能是预防实验动物表皮癌发生的一个相关靶点,并且PGHS-2特异性抑制剂SC-58125作为小鼠皮肤肿瘤促进的有效抑制剂,对人类癌症化学预防可能也很重要。